<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399097</url>
  </required_header>
  <id_info>
    <org_study_id>3830-17-SMC</org_study_id>
    <nct_id>NCT03399097</nct_id>
  </id_info>
  <brief_title>Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery</brief_title>
  <official_title>Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Ofir Harnoy MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The enteroendocrine system is composed from different cells along the different parts of the
      gastrointestinal tract, secreting diverse hormones and bariatric surgery alters intestinal
      hormone secretion, affecting glycemic control and weight. The aim of the study is to
      characterize the composition and secretory profile of enteroendocrine cells in the obese,
      non-obese and non-obese post bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity and Diabetes Mellitus (DM) impose a significant burden of morbidity on many
      individuals around the world. In recent years, the enteroendocrine cells system with its
      diverse hormones (Glucagon, GLP-1, GIP and others) was increasingly recognized as a key
      player in obesity and DM homeostasis.

      Bariatric surgery induces weight loss as well as an improvement in glycemic control often
      leading to diabetes reversal and occasionally to postprandial hypoglycemic events. The aim of
      the study is to characterize the composition and secretory profile of enteroendocrine cells
      in the obese, non-obese and non-obese post bariatric surgery.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    change sites
  </why_stopped>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Actual">July 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization the composition of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery.</measure>
    <time_frame>3 years</time_frame>
    <description>The number of somatostatin, proglucagon and serotonin positive cells in the terminal ileum and Colon by immunohistochemistry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization the secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery.</measure>
    <time_frame>4 YEARS.</time_frame>
    <description>Total hormonal content of somatostatin, proglucagon and serotonin will be quantified using mRNA level qunatitation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Characterization the secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery.</measure>
    <time_frame>4 years</time_frame>
    <description>Total hormonal content of somatostatin, proglucagon and serotonin will be quantified using ELISA.</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterization the location of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery.</measure>
    <time_frame>4 years.</time_frame>
    <description>The location of somatostatin, proglucagon and serotonin will be quantified using ELISA.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>non-obese</arm_group_label>
    <description>non-obese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese</arm_group_label>
    <description>obese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>previously obese</arm_group_label>
    <description>previously obese</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that are referred for screening colonoscopy in the gastroenterology department.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years

          -  BMI&gt;= 35 or BMI&lt;=25 or 6-12 months after RYGB surgery

        Exclusion Criteria:

          -  Known HIV infection

          -  Any NSAID'S usage in the last 3 months

          -  Known Celiac disease

          -  Concomitant disease with potential small bowel or colonic involvement (Tb,
             sarcoidosis, IBD, microscopic colitis etc')

          -  Pregnancy

          -  Participation in another clinical trial

          -  Any use of medications known to modulate glucagon levels such as GLP1 analogs, DPP4
             inhibitors and/or SGLT2 inhibitors.

          -  Insulin-treated patients.

          -  Declined to sign an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Amir Tirosh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ofir Harnoy MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

